Integra LifeSciences Holdings Corporation (IART) Earns Equal Weight Rating from Barclays PLC

Integra LifeSciences Holdings Corporation (NASDAQ:IART)‘s stock had its “equal weight” rating reissued by stock analysts at Barclays PLC in a research report issued on Tuesday. They presently have a $53.00 price objective on the life sciences company’s stock, up from their previous price objective of $47.00. Barclays PLC’s price target indicates a potential downside of 1.17% from the stock’s current price.

A number of other equities analysts have also recently commented on IART. Oppenheimer Holdings, Inc. set a $54.00 price target on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a report on Monday, May 15th. ValuEngine cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Jefferies Group LLC boosted their price target on Integra LifeSciences Holdings Corporation from $52.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, May 31st. UBS AG reissued a “buy” rating and set a $60.00 price target (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Finally, Zacks Investment Research cut Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, June 28th. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $53.54.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 1.42% during mid-day trading on Tuesday, hitting $53.63. The stock had a trading volume of 367,096 shares. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42. The stock has a 50 day moving average price of $50.38 and a 200 day moving average price of $48.14. The firm has a market cap of $4.19 billion, a PE ratio of 65.40 and a beta of 0.73.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting analysts’ consensus estimates of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company had revenue of $282.16 million during the quarter, compared to analysts’ expectations of $283.58 million. During the same quarter in the previous year, the firm earned $0.40 EPS. Integra LifeSciences Holdings Corporation’s revenue was up 13.2% on a year-over-year basis. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Integra LifeSciences Holdings Corporation (IART) Earns Equal Weight Rating from Barclays PLC” was published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/2887191/integra-lifesciences-holdings-corporation-iart-earns-equal-weight-rating-from-barclays-plc.html.

In other news, Director Donald E. Morel, Jr. bought 2,500 shares of the stock in a transaction on Thursday, August 3rd. The stock was acquired at an average price of $49.29 per share, with a total value of $123,225.00. Following the acquisition, the director now directly owns 29,612 shares in the company, valued at $1,459,575.48. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the stock in a transaction on Friday, August 4th. The stock was purchased at an average cost of $49.25 per share, with a total value of $492,500.00. Following the acquisition, the director now owns 29,612 shares in the company, valued at $1,458,391. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 17,550 shares of company stock valued at $864,842. Insiders own 21.50% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 280.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after buying an additional 1,400 shares during the last quarter. Riverhead Capital Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 49.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after buying an additional 799 shares during the last quarter. LS Investment Advisors LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 90.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock valued at $102,000 after buying an additional 1,147 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Integra LifeSciences Holdings Corporation by 223.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after buying an additional 1,751 shares during the last quarter. Finally, Turner Investments LLC bought a new stake in shares of Integra LifeSciences Holdings Corporation in the 1st quarter valued at about $126,000. Hedge funds and other institutional investors own 85.28% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.